戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1          Importantly, Tshr-knockout mice are osteopenic.
2 nchymal stem cells, USP1-deficient mice were osteopenic.
3 nonical Wnt antagonist Dickkopf2 (Dkk2) were osteopenic.
4  mice had grossly normal skeletons, but were osteopenic.
5 re-expressing cells appeared normal but were osteopenic.
6                   Notch2(tm1.1Ecan) mice are osteopenic and have enhanced osteoclastogenesis.
7 s and enhanced mechanical properties in both osteopenic and healthy rodents.
8 ssociated with reduced fracture risk in both osteopenic and osteoporotic patients, whereas bisphospho
9 e effect of anastrozole-induced bone loss in osteopenic and osteoporotic women and might be offered i
10 resorption parameters, although they were as osteopenic as female patients and had low bone formation
11 ous to those in HCS (Notch2HCS) are severely osteopenic because of enhanced bone resorption.
12 opausal women and men at least 50 y old with osteopenic BMD warrant pharmacologic treatment if they h
13 ay broadly benefit in targeted therapies for osteopenic bone defects and cancer bone metastasis.
14                                              Osteopenic bone disease occurs frequently among patients
15 ems such as dental anomalies, short stature, osteopenic bone disease, lactose intolerance, infertilit
16 last and osteoblast numbers and exhibited an osteopenic bone phenotype.
17                                 Twelve obese osteopenic but otherwise healthy subjects (mean age +/-
18 sible therapeutic agent for the treatment of osteopenic conditions, including post-menopausal osteopo
19 proach to the treatment of human age-related osteopenic diseases and postmenopausal osteoporosis.
20 rmacologic design of compounds to ameliorate osteopenic disorders of bone.
21 ation that occurs through TRANCE-RANK causes osteopenic disorders such as osteoporosis and contribute
22 iorate periodontal bone resorption and other osteopenic disorders without affecting inflammation.
23 ion, resulting in reduced bone formation and osteopenic disorders, including osteoporosis, in humans
24                             Transgenics were osteopenic due to decreased osteoblast function in femal
25 ndings, synaptotagmin VII-deficient mice are osteopenic due to impaired bone resorption and formation
26 ased by about 50%, it did not counteract the osteopenic effects of IGF1 on the bone.
27                            In postmenopausal osteopenic females undergoing periodontal maintenance, b
28 dose doxycycline (SDD) in 128 postmenopausal osteopenic females with moderate-to-severe chronic perio
29 f PLCgamma2(-/-) mice, Tmem178(-/-) mice are osteopenic in basal conditions and are more susceptible
30                      When given to normal or osteopenic mice, the compounds increase mineral appositi
31 ss and microarchitecture in SAMP-6 senescent osteopenic mice.
32 e show here that Pax5(-/-) mice are severely osteopenic, missing 60% of their bone mass.
33       Importantly, Pax5-/- mice are severely osteopenic, missing more than 60% of their bone mass.
34 n-periodontitis groups, but when non-smoking osteopenic/osteoporotic periodontitis patients were eval
35 ositively differentiated between healthy and osteopenic/osteoporotic states.
36 ced frequency of clinical attachment loss in osteopenic/osteoporotic women in early menopause.
37     Daily oral administration of NPS 2143 to osteopenic ovariectomized (OVX) rats caused a sustained
38 ve potential clinical significance for older osteopenic patients undergoing reconstructive procedures
39              These outcomes suggest that the osteopenic phenotype associated with DS may be rescued p
40                      I-mfa null mice have an osteopenic phenotype characterized by increased osteocla
41 conductance regulator (Cftr) gene induces an osteopenic phenotype in humans and mice.
42 rgeting F508del-CFTR may rescue the skeletal osteopenic phenotype in murine CF.
43 tion in vitro, which may be a reason for the osteopenic phenotype in the mutant mice.
44 or activity may in part explain the observed osteopenic phenotype of TIEG1 KO mice as well as the kno
45  we report that TREM2-deficient mice have an osteopenic phenotype reminiscent of NHD.
46              Studies in these mice showed an osteopenic phenotype specific to the Pyy-deficient line,
47 ve a normal skeleton at birth but develop an osteopenic phenotype thereafter.
48                              No metabolic or osteopenic phenotype was observed in Ppy-deficient mice.
49 30(Y757F/Y757F)), STAT1 deletion rescued the osteopenic phenotype, indicating a beneficial effect of
50  to this model: first, the rats exhibited an osteopenic phenotype, reminiscent of the bone health tha
51 ncoding FBLP-1) in mice resulted in a severe osteopenic phenotype.
52 he gene encoding ADAR1) resulted in a severe osteopenic phenotype.
53 docrine, cardiopulmonary, thrombophilic, and osteopenic problems.
54 dynamic, hypermetabolic, hypercatabolic, and osteopenic responses in pediatric patients.
55 ur study establishes that PDGFRBD849V causes osteopenic skeletal phenotypes that are associated with
56 ls, Osx::CXCR4(fl/fl) mice developed smaller osteopenic skeletons as evidenced by reduced trabecular
57 s and matrix properties, suggesting that the osteopenic Smad3-/- phenotype may be, in part, secondary
58  Cyclosporin and tacrolimus lead to a severe osteopenic state in rats, but the skeletal toxicity of t
59                                      In some osteopenic states, such as osteogenesis imperfecta and s
60 annot produce or respond to estrogen (E) are osteopenic, suggesting that E may regulate bone turnover
61 rozygotic and homozygotic TSHR null mice are osteopenic with evidence of enhanced osteoclast differen
62 ns should make the decision whether to treat osteopenic women 65 years of age or older who are at a h
63 t-term dose-response trial in postmenopausal osteopenic women are necessary to inform the design of r
64 the effect of risedronate versus placebo for osteopenic women in stratum II randomly allocated to ana
65 xycycline (SDD) treatment of post-menopausal osteopenic women significantly reduced periodontal disea
66 omized controlled trial of 78 postmenopausal osteopenic women supplemented with calcium (1200 mg/d),
67 rom ovariectomized animals to postmenopausal osteopenic women through evaluation of bioavailability,
68                            In postmenopausal osteopenic women undergoing periodontal maintenance, bas
69                          128 post-menopausal osteopenic women with chronic periodontitis randomly rec
70 bial doxycycline (SDD) in 128 postmenopausal osteopenic women with moderate to severe chronic periodo
71 twice a day) was evaluated in postmenopausal osteopenic women with periodontitis in a double-blind, p
72 ailable estimates of alendronate efficacy in osteopenic women.